title: Nanomedicines in the EU-Regulatory Overview.
abstract: This article provides an overview of the European Union (EU) framework for the marketing authorisation of medicinal products, at both European and National level, and aims to demonstrate the current position and experience with nanomedicines. It will be described how the EU promotes the development of new nanomedicines by publishing guidance, providing scientific advice and engaging with multiple regions for the convergence of scientific requirements to support the quality, safety and efficacy of nanomedicines. It will also be highlighted the regulatory challenges deriving from the use of an innovative technology that crosses different platforms and the importance of overcoming challenges for the benefit of public health.
authors.affiliation: European Medicines Agency, London, UK. ruben.pita@ema.europa.eu.
authors.forename: Ruben
authors.initials: R
authors.lastname: Pita
authors.affiliation: European Medicines Agency, London, UK.
authors.forename: Falk
authors.initials: F
authors.lastname: Ehmann
authors.affiliation: European Medicines Agency, London, UK.
authors.forename: Marisa
authors.initials: M
authors.lastname: Papaluca
mesh_terms: D005062:European Union; D006801:Humans; D007880:Legislation, Drug; D050997:Nanomedicine
keywords: EMA; EU; innovation; nanomedicine; regulatory science